Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
A new analysis finds that relatively minor changes to Medicare's payment policies could help jump-start the fledgling market for biosimilars.
Where it stands: The market for biosimilars is weak, and that means the drugs' expected savings aren't materializing. But Medicare could help kick things up a notch, according to Avalere estimates commissioned by a coalition of biosimilars manufacturers.
By the numbers: According to Avalere's calculations, biosimilars could reach somewhere between 26% and 46% market share if Medicare picked up the tab for seniors' out-of-pocket costs for the drugs.
- That approach could save the government as much as $5 billion and seniors as much as $3 billion over 10 years, depending on the details, the analysis says.
How it works: Doctors' financial incentives matter just as much as patients', since most biologics and biosimilars are administered at a doctor's office.
- Medicare could save billions over the long run by simply tacking on a payment bonus for biosimilars, the analysis says.
- Letting doctors share in the savings that biosimilars bring to Medicare wouldn't save as much money, but would do more to help biosimilars as a class gain a stronger competitive footing.
Go deeper: How to jump-start a fledgling class of new, cheaper drugs